Skip to main content

Table 2 Efficacy at weeks 2, 6, and 12

From: Kunxian capsules in the treatment of patients with ankylosing spondylitis: a randomized placebo-controlled clinical trial

Activity index

Time

Mean ± SD change from the baseline

Kunxian, n = 35

Placebo, n = 33

BASDAI (0–10), mean (±SD)

Week 2

-1.46 ± 1.61

-0.91 ± 1.31

 

Week 6

-1.98 ± 1.48a

-0.10 ± 1.13

 

Week 12

-1.68 ± 1.70

-1.11 ± 1.17

BASFI (0–10), mean (±SD)

Week 2

-0.52 ± 1.17

-0.15 ± 1.32

 

Week 6

-0.88 ± 1.18c

-0.28 ± 1.27

 

Week 12

-0.75 ± 2.26

-0.01 ± 1.59

ASDAS-CRP, mean (±SD)

Week 2

-0.84 ± 0.91b

-0.05 ± 0.98

 

Week 6

-1.25 ± 0.95a

-0.06 ± 0.70

 

Week 12

-1.08 ± 1.03b

-0.11 ± 1.79

ESR (mm/h), mean (±SD)

Week 2

-11.26 ± 16.38c

0.15 ± 9.48

 

Week 6

-16.26 ± 18.63b

0.71 ± 16.76

 

Week 12

-14.51 ± 22.65c

0.09 ± 16.50

CRP (ref 6 mg/l), mean (±SD)

Week 2

-16.49 ± 21.12b

0.37 ± 16.55

 

Week 6

-20.66 ± 23.71b

1.07 ± 20.20

 

Week12

-18.50 ± 26.18c

0.76 ± 16.67

Level of morning stiffness, 0–10 cm VAS

Week2

-2.56 ± 2.81c

-0.88 ± 1.37

 

Week6

-2.10 ± 2.39c

-0.78 ± 2.38

 

Week 12

-2.53 ± 2.60c

-1.34 ± 1.67

Global assessment, 0–10 cm VAS

Week 2

-1.29 ± 1.94

-0.54 ± 1.30

 

Week 6

-1.99 ± 2.10c

-0.81 ± 1.31

 

Week 12

-1.69 ± 2.30

-0.85 ± 1.55

Total back pain, 0–10 cm VAS

Week 2

-1.22 ± 1.99

-0.45 ± 1.60

 

Week 6

-1.97 ± 2.08c

--0.81 ± 1.98

 

Week 12

-1.94 ± 2.17c

-0.77 ± 1.57

Swollen joints, range 0–44

Week 2

-0.14 ± 0.42

0.14 ± 0.85

 

Week 6

-0.16 ± 0.5

-0.05 ± 0.34

 

Week 12

0 ± 0.82

-0.06 ± 0.34

Tender joints, range 0–44

Week 2

-1.19 ± 2.77

-0.35 ± 0.73

 

Week 6

-2.38 ± 3.66c

-0.26 ± 1.24

 

Week 12

-2.89 ± 3.43c

-0.36 ± 1.32

BASMI (0–10), mean (±SD)

Week 2

-0.32 ± 0.94

-0.32 ± 0.97

 

Week 6

-0.49 ± 1.10

-0.14 ± 0.98

 

Week 12

-0.24 ± 1.09

-0.21 ± 0.95

  1. aCompared with placebo group. p< 0.0001
  2. bCompared with placebo group. p< 0.001
  3. cCompared with placebo group. p < 0.05